

EVOTEC ADDS CELL THERAPY MANUFACTURING FACILITY WITH ACQUISITION OF RIGENERAND

- ▶ *EVOTEC'S **EVOCELLS** PLATFORM INTEGRATES INNOVATIVE OFF-THE-SHELF IPSC CELL THERAPY DISCOVERY WITH DEVELOPMENT AND MANUFACTURING*

Hamburg, Germany, 30 May 2022:

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the signing of a definitive agreement under which Evotec will acquire 100% of the capital of Rigenrand Srl, a leading cell technology company, for a purchase price of € 23 m. Founded in 2009 as a spin-off of the University of Modena and Reggio Emilia, Rigenrand is a pioneering company in the field of cGMP manufacturing of cell therapies. The acquisition adds a great team of cell therapy cGMP manufacturing experts to Evotec.

Rigenrand is based in Medolla, Italy, approx. 100 km south of Evotec's Campus Levi-Montalcini in Verona. With their highly specialised team, Rigenrand operates a first-class certified facility that integrates state-of-the-art cGMP production with R&D and QC labs and development labs. The production facility, called "cell factory", comprises a series of fully equipped clean rooms for the manufacturing of complex cell-based therapies. In total, the site in Medolla close to Modena comprises 1,200 sqm of high-tech manufacturing space, with potential for significant further expansion.

The acquisition expands Evotec's cell therapy platform **EVOcells** by adding a dedicated, high-quality cGMP manufacturing site. The seamless integration of discovery and development of innovative cures combined with in-house capabilities in GMP manufacturing are mandatory within this field. While the revenue contribution will not be significant at the beginning, the manufacturing capability of Rigenrand along with the exceptional R&D power of Evotec will strengthen Evotec's ability to successfully win new integrated partnerships within the innovative field of cell therapy.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "Cell therapies are an exciting emerging therapeutic modality with broad applicability across many indications. Originating from our leading iPSC platform, Evotec's **EVOcells** platform enables the delivery of innovative cell therapeutics from inception

to the patient. The acquisition of Rigenrand adds manufacturing capacity and expertise to the **EVOcells** platform. Our conversations with our partners as well as our own industry observations have made it clear that horizontal expansion and rapid iteration at the scale-up are critical within the cell therapy space. As we see very strong demand for our standalone Just – Evotec Biologics J.POD®s in the US and EU, it is strategically the logical step to build separate capability and capacity internally. We warmly welcome the Rigenrand team into the Evotec family and are excited to leverage their skill and expertise for our partners and ultimately the patients.”

Prof. Massimo Dominici, founder and CSO of Rigenrand and Professor of Oncology at the University of Modena and Reggio Emilia, said: “The combination of Rigenrand and Evotec is a unique opportunity to grow and a natural evolution for our team. The field of cell therapies is rapidly expanding with new products and novel technologies requiring R&D skills, flexibility in manufacturing and experience in pharmaceutical development. Evotec’s **EVOcells** platform and Rigenrand’s technologies and capacity to transform cells into therapeutic products combining an R&D vocation and manufacturing skills, is a unique combination with technological and logistic synergies that will make a very relevant impact in the cell therapy field with a state-of-the art cGMP Technological Center for Cell Therapy Manufacturing at a European scale.”

Luca Marini, CEO of Xyence Capital SGR, the majority shareholder of Rigenrand, said: “We are very proud of the success of this deal because it shows our expertise in identifying high-potential scientific areas, such as cell therapies, and in providing a fair financial return to our investors that have chosen to contribute to the incubation and growth of Rigenrand since 2016. Evotec is the optimal industrial partner to bring Rigenrand to further global growth. Last but not least, we are happy to have created the conditions for a number of benefits for the local economy, as well as the basis for an evident scientific progress that remains the purpose and ethical core of our investment philosophy.”

About Cell Therapy and EVOcells

Cell therapy is a recent and innovative therapeutic modality that has the potential to deliver unprecedented therapeutic effects. Cell therapies can be used as a regenerative strategy, replacing a patient’s dysfunctional cells or are used as adoptive immunotherapy to help the immune system fight cancer. Sources for cell therapeutics range from the patient’s own material, a healthy donor or from stem cells. The advent of induced pluripotent stem cells (“iPS cells” or “iPSCs”) that can be generated directly from somatic cells has opened up stem cells as an almost unlimited source of

consistent-quality material for such cell therapies. iPSC-derived, off-the shelf therapeutics are considered to be one of the most promising approaches in the cell therapy space.

Building on its many years of experience with iPSCs, Evotec has developed **EVOcells** as an integrated, versatile platform for the discovery, development and manufacturing of cell therapies. The Company's aim is to develop innovative but cost-effective therapies for large patient numbers based on human cells to cure life-threatening diseases. Evotec's current **EVOcells** project portfolio covers immuno-oncology, metabolic diseases, heart repair as well as exosome-based therapies. Evotec leverages the **EVOcells** platform for both proprietary and partnered projects, and is aiming to accelerate these projects towards transformative therapies, both within existing and new disease areas.

ABOUT EVOTEC SE

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,200 highly qualified people. The Company's 15 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter [@Evotec](https://twitter.com/Evotec) and [LinkedIn](https://www.linkedin.com/company/evotec).

FORWARD-LOOKING STATEMENTS

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.